A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 mg/week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Latest Information Update: 02 Nov 2021
At a glance
- Drugs TV 1380 (Primary)
- Indications Cocaine-related disorders
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 01 Jul 2014 Status changed from recruiting to completed, as per European Clinical Trials Database record.
- 11 Oct 2013 New trial record